- Exploration of thrombotic microangiopathy (TMA) and its relationship to aGVHD.
- Causes of complications of disease (COD) in transplant patients.
- Key serum biomarkers used in monitoring aGVHD.
- How biomarkers can indicate disease severity and treatment response.
- Limitations of relying solely on clinical symptoms versus biomarker results.
- Factors contributing to mismatches between biomarkers and clinical symptoms.
Length of Presentation: 23 minutes (Part 4 of 4)